01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. stock news by MarketWatch. This news release constitutes a “designated news release” for the purposes of the Company’s. Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the strengthening of its global commercial. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. We also use them to share usage. We also use them to share usage. 1300 (+9. 60%. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. THERATECHNOLOGIES INC. Theratechnologies Inc. Metastasis is a form of cancer that has spread from its original site to a distant site or organ where it grows or metastasizes. By continuing to use our service, you agree to our use of cookies. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. $103. Proceeds to Be Used to Redeem All of the Outstanding 5. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 08). The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. By continuing to use our service, you agree to our use of cookies. . , that crews have been mobilized to prepare for the 2022 exploration program at the Treaty Creek property, located in the heart of the. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Aug. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. CA, an investment chat community for Canada's small cap marketsTheratechnologies is currently analyzing data and preparing responses to questions received from the FDA. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. Theratechnologies inc. 4% from the stock's current price. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement. The firm offers its product under the brand name of. 250 Howe Street, Suite 1400 Vancouver, British Columbia, V6C 3S7 Click to expand. com uses cookies on this site. This news release constitutes a "designated news release" for the purposes of. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We also use them to share usage information with our partners. SORT1 is a “scavenger” receptor that plays a significant role in protein internalization, sorting, and. Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. - Q3 2022 Consolidated. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. Stockhouse. 63. On average, they expect the company's stock price to reach $36. This peptide-drug conjugate (PDC) is the lead candidate stemming from Theratechnologies’ SORT1+ Technology™ in oncology. . Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. Remember, high Theratechnologies' alpha is almost always a sign of. 1M. 5000 +0. If you have JavaScript enabled then this page should refresh automatically, if it does not then please tap the button below. 617-356-1009. Gary Littlejohn Stockhouse. 74M. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers Stockhouse. Stockhouse. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. – Form 40-F for Fiscal Year Ended November 30, 2011 – Your File No. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April 12. Senior Director, Communications & Corporate Affairs. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. : 001-35203 Mr. 66% compared to the previous year's 69. 67% from the latest price. (Image via Theralase Technologies Inc. (THTX) stock quote, history, news and other vital information to help you with your stock trading and investing. TO) Stock Price, News, Quote & History - Yahoo Finance Canada Markets close in 43 mins S&P/TSX 20,125. Stockhouse. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com. Theratechnologies presented the pre-clinical and clinical data gathered thus far to the SAC, which made recommendations to modify the frequency of administration, selection of tumor types and. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. com. 8. 2% per year. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. Company Type For Profit. We currently market prescription products for people with HIV in the United States. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to. In 2022, THTX's revenue was 80. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. Gary Littlejohn. com uses cookies on this site. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced public offering (the “Public. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. T. Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. October 13, 2022 07:30 ET | Source: Theratechnologies. US Headquarters. We currently market prescription products for people with HIV in the United States. 89 $2. [email protected] Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update T. MONTREAL, Jan. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. Theratechnologies, Inc. During the last trading day the stock fluctuated 4. Theratechnologies Inc. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. com uses cookies on this site. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. Image source: The Motley Fool. It is the Company’s proprietary. 2. Trogarzo® and. This news release constitutes a. Phone Number (514) 336-7800. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. 4% annually. com uses cookies on this site. MONTREAL, Jan. By continuing to use our service, you agree to our use of cookies. 2% to $21. Betteryear2. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical. Theratechnologies Inc. . (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. Theratechnologies reduces R&D head count to compensate for sales setback. (TSX:TH) announced new data from a tissue microarrays study which demonstrated high expression of sortilin 1 in solid tumors. We also use them to share usage information with our partners. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (2021-11-23 | TSX:TH) Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended. During the last trading day the stock fluctuated 12. THTX | Complete Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Montréal, Québec, Canada . TH1902 is a first-in-class PDC targeting SORT1, that consists of 2 molecules of docetaxel attached to the TH19P01 peptide via a cleavable succinyl linker. 54% and a negative trailing twelve-month return on equity of 1,116. , Senior Vice President and Chief Medical Officer, Theratechnologies commented, “The exciting new data in triple negative breast and ovarian cancer demonstrate. The FDA granted fast track designation to TH1902 as a single agent for. - TH1902 Phase 1 basket trial proceeding as planned. 00%. View real-time stock prices and stock quotes for a full financial overview. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. The price has fallen in 5 of the last 10 days. CALGARY, AB, May 12, 2022 /PRNewswire/ - Exro Technologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Cookies are used to offer you a better browsing experience and to. com uses cookies on this site. com uses cookies on this site. - On track to meet FY2022. Theratechnologies inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal. Theratechnologies Inc. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. . acts as investment manager. H. (2013-04-03 | TSX:TH) Theratechnologies Inc. Stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. - Cash, bonds and money market funds of US$22. We currently market prescription products for people with. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). A live webcast of Dr. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. R. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. The company had revenue of $20. 74M. Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022. (NASDAQ:NASDAQ:THTX) Q1 2021 Earnings Conference Call April 14, 2021 8:30 AM ETCompany ParticipantsDenis Boucher - Vice President,. Further. Agreement in principle on key amendments to loan. (2013-04-03 | TSX:TH) Theratechnologies Inc. Investor Relations. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. - Q3 2022 North American Revenue Growth of 19%. 4. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. European Headquarters. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. com. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. MONTREAL, Jan. Cookies are used to offer you a better browsing experience and to analyze our traffic. 26 +15. 17% from a day low at $1. UN) today announces steps to strengthen its financial position, including financing and disposition initiatives, and a reduction to its monthly distribution. We currently market prescription products for people with HIV in the United States. 9% more than in 2021. See a list of the most recent Stock Forum posts on Stockhouse. TH | October 13, 2022. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. com uses cookies on this site. Stockhouse. Browse posts by Sector and Subsector. Type: Company - Public (TH) Revenue: $5 to $25 million (USD) Biotech & Pharmaceuticals. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. View real-time stock prices and stock quotes for a full financial overview. Vice President, Communications and Corporate Affairs. This news release constitutes a “designated news release” for the purposes. Contact Email communications@theratech. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. A high-level overview of Theratechnologies Inc. Stockhouse. US Headquarters. Cookies are used to offer you a better browsing experience and to analyze our traffic. Market Cap. 9 million as at August 31, 2023. 72%. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed. Theratechnologies (THTX) Stock Price, News & Analysis $1. Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of. Stockhouse. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on. By continuing to use our service, you agree to our use of cookies. A high-level overview of Theratechnologies Inc. 11/05/2020 4:15:02 PM. 5%. We also use them to share usage. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. FAQ – Émetteurs inscrits NOUVEAU. com uses cookies on this site. F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophy. 2% for this period. (2020-10-22 | TSX:TH) Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020. , a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. - Issued and outstanding common shares to be consolidated on the basis of 1 post. - Cash, bonds and money market funds of US$22. Further. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in. By continuing to use our service, you agree to our use of cookies. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. Following the release, Knight will hold a conference call and audio webcast. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. S. Cookies are used to offer you a better browsing experience and to analyze our traffic. (2022-04-27 | TSX:TH) Theratechnologies to Focus Its Commercialization Activities on the North American Territory. Stockhouse. TH | May 19, 2023. According to 3 analysts, the average rating for THTX stock is "Buy. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. Stockhouse. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. Their THTX share price targets range from $36. By continuing to use our service, you agree to our use of cookies. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays. US Headquarters. TH | February 28, 2023. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (THTX) stock. Theratechnologies layoffs. B2Gold Declares Fourth Quarter 2023 Dividend. (2021-06-30 | TSX:TH) CORRECTION: Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021. Further. stockhouse. 2. Theratechnologies Appoints New Board Member. com uses cookies on this site. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Shares of Theratechnologies are up 4. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. Katana shareholders will. TORONTO, May 19, 2023. 617-356-1009. 38. Montréal, Québec, Canada . Patient assistance: 833-238-4372. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023. Marsolais’ presentation will be available through. View recently published Stock News reports from independent reports and journalists. org. Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. THERATECHNOLOGIES INC. Cookies are used to offer you a better browsing experience and to analyze our traffic. 521. (“Theratechnologies”) with the Securities and Exchange Commission (the. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. Stockhouse. Cookies are used to offer you a better browsing. By continuing to use our service, you agree to our use of cookies. We also use them to share usage information with our partners. MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. Further information about Theratechnologies is available on the Company's website at on SEDAR at and on EDGAR at MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. T. Stockhouse. licensed the product from TaiMed Biologics, Inc. FY2022 revenue. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. . com uses cookies on this site. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. : Renegotiated Lease to Generate Substantial Annual Savings Stockhouse. M. 1-514-336-7800. Theratechnologies Appoints New Board Member. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. is a pharmaceutical company. - October 10, 2023) - KO Gold Inc. MONTREAL, Sept. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in three poster presentations at the 2022 Annual Meeting. communications@theratech. (2015-05-15 | TSX:TH) Authorization to Discontinue Class Action Proceedings Against Theratechnologies Granted. 49%) At close: 04:00PM EST 1. ir@theratech. Cookies are used to offer you a better browsing experience and to analyze our traffic. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xToronto, Ontario-- (Newsfile Corp. Visit the TSX ETF Investor Centre to access our screener and comparison tool. MONTREAL, Jan. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. Top 173 largest Canadian Companies in the Drug Manufacturers—Specialty & Generic industry by Market Cap. MONTREAL, Feb. Stockhouse. GlobeNewswire. 00. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. - 2023 Q3 positive adjusted EBITDA to be achieved. Story. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. 0. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1. MONTREAL, Sept. $109. MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Senior Director, Communications & Corporate Affairs. 23) diluted earnings per. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. This module allows you to check different measures of market premium (i. Theratechnologies Inc. . The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective. com uses cookies on this site. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. MONTREAL, Aug. sBLA for F8 formulation of tesamorelin submitted to FDA. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as compared to the 2021 fiscal year. Theratechnologies Inc. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers. , a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced further changes to its operations that will see a tapering. 86 million for the quarter. E-Poster website launch date and time: Saturday, April 10, 2021, 8:30 AM. The company reported ($0. One reason for that is that this tier does not include penny stocks. . $30. La Bourse de Toronto a clôturé en hausse mardi pour une troisième séance consécutive, tandis que les grands indices boursiers américains ont avancé eux aussi. Overview Stock Screener Earnings Calendar Sectors Nasdaq | THTX U. Theratechnologies Inc.